Assenagon Asset Management
MLNT

Assenagon Asset Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Assenagon Asset Management’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-35,079
Closed -$139K – 1201
2018
Q4 		$139K Buy
+35,079
New +$449K ﹤0.01% 977

Other funds holding MLNT

IP
Isthmus Partners Madison, Wisconsin $953M AUM 18.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ZIM
Zacks Investment Management Chicago, Illinois $12.5B AUM 29.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Assenagon Asset Management's MLNT Position: Q1 2019 in Review

Assenagon Asset Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2019, closing a stake of 35,079 shares — an estimated $139K sold.

Assenagon Asset Management first reported a position in MLNT in Q4 2018 and held it in 1 quarter. The position peaked at $139K in Q4 2018. 52 funds tracked by Wall St. Rank hold MLNT as of Q1 2019.

  • Assenagon Asset Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Assenagon Asset Management sold 35,079 Melinta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $139K.
  • Assenagon Asset Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Assenagon Asset Management's Melinta Therapeutics, Inc. Common Stock position peaked at $139K in Q4 2018.
  • 52 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Assenagon Asset Management's 13F filing for Q1 2019, filed 26 Apr 2019.